Cover Image

A pathological complete response to capecitabine plus oxaliplatin regimen combined with tislelizumab in advanced gastric cancer with liver metastases: A case report

A 66-year-old female patient presenting with dysphagia was diagnosed with stage IV unresectable gastric cancer (cTxN+M1). Multiple liver metastases were identified. The patient subsequently underwent five courses of chemotherapy and immunotherapy, including the capecitabine plus oxaliplatin (XELOX)...

Full description

Saved in:

Bibliographic Details
Main Authors:	Li-Ping Sheng (Author), Yun-Lin Huang (Author), Zhi Wang (Author), Hai-Fang Zhang (Author), Jin-Yan Zhang (Author), Xiao-Yi Lei (Author)
Format:	Book
Published:	Taylor & Francis Group, 2024-12-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Cost-Effectiveness Analysis of Capecitabine Plus Oxaliplatin Versus Gemcitabine Plus Oxaliplatin as First-Line Therapy for Advanced Biliary Tract Cancers
by: Ruijia Chen, et al.
Published: (2022)

Cost-effectiveness analysis of tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced gastric or gastroesophageal junction adenocarcinoma: perspectives from the United States and China
by: Wenwang Lang, et al.
Published: (2024)

Cost-effectiveness analysis of first-line tislelizumab plus chemotherapy for recurrent or metastatic nasopharyngeal cancer
by: Zhengda Pei, et al.
Published: (2023)

Intracranial Efficacy of Pyrotinib and Capecitabine Combination Therapy in HER2-Positive Breast Cancer with Brain Metastases
by: Wang C, et al.
Published: (2024)

Comparative efficacy and safety of Chinese medicine injections combined with capecitabine and oxaliplatin chemotherapies in treatment of colorectal cancer: A bayesian network meta-analysis
by: Shuzhen Liu, et al.
Published: (2022)

Cytotoxic effects of the newly-developed chemotherapeutic agents 17-AAG in combination with oxaliplatin and capecitabine in colorectal cancer cell lines
by: Mahshid Mohammadian, et al.
Published: (2017)

Cost-Effectiveness Analysis of Tislelizumab Plus Chemotherapy as First-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma in China
by: Zhou C, et al.
Published: (2023)

Dihydropyrimidine Dehydrogenase Levels in Colorectal Cancer Cells Treated with a Combination of Heat Shock Protein 90 Inhibitor and Oxaliplatin or Capecitabine
by: Mahshid Mohammadian, et al.
Published: (2019)

Oxaliplatin(IV) Prodrugs Functionalized with Gemcitabine and Capecitabine Induce Blockage of Colorectal Cancer Cell Growth-An Investigation of the Activation Mechanism and Their Nanoformulation
by: Carlo Marotta, et al.
Published: (2024)

The Pathologic Complete Response Ratio of Liver Metastases Represents a Valuable Prognostic Indicator
by: Yanbo Xu, et al.
Published: (2022)

The Cost-Effectiveness of Tislelizumab Plus Chemotherapy for Locally Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer
by: Xia Luo, et al.
Published: (2022)

Feasibility of sequential adjuvant chemotherapy with a 3-month oxaliplatin-based regimen followed by 3 months of capecitabine in patients with stage III and high-risk stage II colorectal cancer: JSWOG-C2 study
by: Tsuruta A, et al.
Published: (2016)

Melanoma with gastric metastases
by: Katherine Wong, et al.
Published: (2016)

Cost-effectiveness analysis of tislelizumab plus chemotherapy as the first-line treatment for advanced or metastatic esophageal squamous cell carcinoma in China
by: Yanhong Liu, et al.
Published: (2024)

Metastases to the Stomach: Clinicopathologic Features of Metastases Mimicking Gastric Primaries
by: Ali Yılmaz ALTAY, et al.
Published: (2021)

Tislelizumab plus chemotherapy versus pembrolizumab plus chemotherapy for the first-line treatment of advanced non-small cell lung cancer: systematic review and indirect comparison of randomized trials
by: Yimeng Guo, et al.
Published: (2023)

Pathological complete remission of a locally advanced gastric cancer by neoadjuvant therapy "sandwich" regimen as SOXAP+ fluorescence laparoscopic surgery +SOXAP: Case report
by: Yanling Ma, et al.
Published: (2022)

Cutaneous metastases from gastric adenocarcinoma
by: Asli Turgut Erdemir, et al.
Published: (2011)

Model‐based population pharmacokinetic analysis of tislelizumab in patients with advanced tumors
by: Nageshwar Budha, et al.
Published: (2023)

Pharmacoeconomic analysis of trastuzumab emtanzine comparing to lapatinib + capecitabine in pa-tients with HER2+ breast cancer and central nervous system metastases
by: A. S. Kolbin, et al.
Published: (2018)

Synchronous endometrial and gastric metastases of invasive lobular breast carcinomas
by: Mei-Ju Lai, et al.
Published: (2016)

Effect of capecitabine on breast cancer patients with different estrogen receptor status
by: Gang Xu, et al.
Published: (2020)

Tislelizumab plus chemotherapy is more cost-effective than chemotherapy alone as first-line therapy for advanced non-squamous non-small cell lung cancer
by: Xueyan Liang, et al.
Published: (2023)

Co-enrichment of CD8-positive T cells and macrophages is associated with clinical benefit of tislelizumab in solid tumors
by: Dingwei Ye, et al.
Published: (2023)

Clinical dose rationale of tislelizumab in patients with solid or hematological advanced tumors
by: Tian Yu, et al.
Published: (2024)

Cutaneous Metastases as a First Sign of Gastric Adenocarcinoma
by: Marta Prtajin, et al.
Published: (2024)

Multiple cutaneous melanomas associated with gastric and brain metastases
by: Lara Caroline Grander, et al.
Published: (2016)

Cutaneous metastases from gastric adenocarcinoma 15 years after curative gastrectomy
by: Fang Liu, et al.
Published: (2015)

Akkermansia muciniphila-derived pentadecanoic acid enhances oxaliplatin sensitivity in gastric cancer by modulating glycolysis
by: Qixuan Xu, et al.
Published: (2024)

Case report: Cutaneous metastases as a first manifestation from breast cancer with concurrent gastric metastases
by: Lulu Xu, et al.
Published: (2024)

Cost-effectiveness analysis of the tislelizumab versus docetaxel for advanced or metastatic non-small-cell lung cancer in China
by: Xiaoyu Zhang, et al.
Published: (2024)

Hand-foot syndrome due to capecitabine
by: Surjushe Amar, et al.
Published: (2009)

Hand-foot syndrome due to capecitabine
by: Surjushe Amar, et al.
Published: (2008)

A phase I/II study of biweekly capecitabine and irinotecan plus bevacizumab as second-line chemotherapy in patients with metastatic colorectal cancer
by: Suenaga M, et al.
Published: (2015)

Economic evaluation of tislelizumab versus chemotherapy as second-line treatment for advanced or metastatic esophageal squamous cell carcinoma in China
by: Fenghao Shi, et al.
Published: (2022)

Protocol of REACH-01: a single-arm, open label, prospective study of HAIC sequential TAE combined with tislelizumab and surufatinib in unresectable intrahepatic cholangiocarcinoma
by: Kang-shuai Li, et al.
Published: (2024)

Clinical benefits of oral capecitabine over intravenous 5-fluorouracyl regimen in case of neoadjuvant chemoradiotherapy followed by surgery for locally advanced rectal cancer
by: Attila Paszt, et al.
Published: (2022)

METTL3 promotes drug resistance to oxaliplatin in gastric cancer cells through DNA repair pathway
by: Yi Wang, et al.
Published: (2023)

Inflammatory melanoma in transit metastases with complete response to talimogene laherparepvec
by: Jonathan T. Blackmon, et al.
Published: (2017)

Capecitabine-induced Subacute Cutaneous Lupus Erythematosus
by: Aroni Rocha, et al.
Published: (2019)